TLR9-targeted CpG immunostimulatory treatment of metastatic melanoma: A phase II trial with CpG 7909 (ProMune) No significant financial relationships to disclose. This is an ASCO Meeting Abstract from ...
Clinical utility and actionability of a combinatorial approach utilizing molecular diagnosis and biomarker profiling for cancers with unknown or differential diagnoses that were diagnosed as NSCLC.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback